Comparison of adverse events during capecitabine versus 5-fluorouracil/oxaliplatin adjuvantchemotherapy for stage II/III colon cancer: A population based analysis.

被引：0
|
作者：
Pabani, Aliyah
Mazurek, Matthew
Cheung, Winson Y.
Spratlin, Jennifer L.
Hiller, Julie A. Price
Standeven, Leah Jean
Mulder, Karen E.
Ghosh, Sunita
Ho, Maria Yi
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14663
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer A Population-Based Analysis
    Sanoff, Hanna K.
    Carpenter, William R.
    Freburger, Janet
    Li, Ling
    Chen, Kun
    Zullig, Leah L.
    Goldberg, Richard M.
    Schymura, Maria J.
    Schrag, Deborah
    CANCER, 2012, 118 (17) : 4309 - 4320
  • [2] 5-Fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer
    Seitz, JF
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 41 - 44
  • [3] Pharmacoeconomic Analysis of Capecitabine versus 5-Fluorouracil/Leucovorin as Adjuvant Therapy for Stage III Colon Cancer in Taiwan
    Hsu, Tzu-Chi
    Chen, Hong-Hwa
    Yang, Ming-Chin
    Wang, Hwei-Ming
    Chuang, Jye-Hann
    Jao, Shu-Wen
    Chiang, Hsin-Chieh
    Wen, Chung-Yu
    Tseng, Jen-Hao
    Chen, Li-Tzong
    VALUE IN HEALTH, 2011, 14 (05) : 647 - 651
  • [4] Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Twelves, C.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (02): : 72 - 73
  • [5] Is oxaliplatin combined with weekly bolus 5-fluorouracil and leucovorin an option for stage II and III colon cancer?
    Chris Twelves
    Nature Clinical Practice Oncology, 2008, 5 : 72 - 73
  • [6] Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66 years or older
    Jones, Emily
    Duan, Zhigang
    Nguyen, Thinh T.
    Giordano, Sharon H.
    Zhao, Hui
    CANCER MEDICINE, 2023, 12 (03): : 2389 - 2406
  • [7] Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin
    Dencausse, Y
    Hartung, G
    Sturm, J
    Kopp-Schneider, A
    Hagmüller, E
    Wojatschek, C
    Lindemann, H
    Fritze, D
    Queisser, W
    ONKOLOGIE, 2002, 25 (05): : 426 - 430
  • [8] Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201-An updated survival analysis.
    Nimeiri, Halla Sayed
    Feng, Yang
    Catalano, Paul J.
    Meropol, Neal J.
    Giantonio, Bruce J.
    Sigurdson, Elin R.
    Martenson, James A.
    Whitehead, Robert P.
    Sinicrope, Frank A.
    Mayer, Robert J.
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US
    Aballea, Samuel
    Chancellor, Jeremy V. M.
    Raikou, Maria
    Drummond, Michael F.
    Weinstein, Milton C.
    Jourdan, Sophia
    Bridgewater, John
    CANCER, 2007, 109 (06) : 1082 - 1089
  • [10] Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer
    DiPetrillo, T. A.
    Pricolo, V.
    Sikov, W. M.
    Lagares-Garcia, J.
    Vrees, M.
    Oldenburg, N.
    Khurshid, H.
    McNulty, B.
    Shipley, J.
    Safran, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345